Regulus Forms Division to Develop microRNA Disease Biomarkers | GenomeWeb

Regulus Therapeutics this week announced today that it has established a new research and development division that will focus on the identification of miRNAs as disease biomarkers.

Called Regulus microMarkers, the new unit will further develop Regulus' technology for extracting, profiling, and analyzing miRNAs, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.